Privi Speciality Chemicals Ltd

- The company plans a capital expenditure (capex) of around INR 250-300 crores over the next 15 to 18 months for capacity expansion, including debottlenecking and new products. - This capex will be funded through a mix of internal accruals and debt. - The balance sheet is strong enough to support additional borrowing, and the immediate capex needs will be met through internal accruals and debt. - Fundraising through Qualified Institutional Placement (QIP) or equity may be considered in the future based on requirements, but there is no immediate plan. - The company will take a call on any potential fundraises at an opportune time, depending on the demand and market environment.

- Privi Specialty Chemicals plans a capex of INR 250-300 crores over the next 15-18 months for capacity expansion and debottlenecking of flagship products. - This capex includes increasing existing product capacities and setting up capacities for a few new products. - New products under development will form the next phase of expansion, for which Environmental Clearances (EC) and permissions have already been applied. - The capex will be funded through a mix of internal accruals and debt. - No immediate fundraising like QIP is planned; however, it may be considered in the future based on requirements. - The company is also exploring co-manufacturing arrangements with competitors, though details are confidential. - Continuous process development and greenfield projects (e.g., JV with Givaudan) are part of growth strategy. - Capacity enhancements and new product launches aim to support 20%+ revenue growth in coming years.

- The company is very bullish about growth, aiming for a minimum of 20% revenue growth for FY 2025-26, with volume growth around 15%. - A healthy order booking position of 65-70% for calendar year 2025 supports this confidence. - Product mix improvements and internal efficiency enhancements contribute to margin sustainability and growth. - Expansion through capacity increases and debottlenecking will support volume growth over the next 1-2 years. - New product development, including high-value specialty products and new flagship products, will add to growth. - Geographical expansion into markets like India, Africa, South Asia, and China is expected to drive growth, with >20% growth anticipated from Indian and African markets. - The Givaudan JV is ramping up and on track, supporting future revenue increases. - Ongoing R&D and planned capacity expansions worth INR 250-300 crores over 15-18 months will facilitate this growth.

- The company is confident of maintaining a minimum 20% revenue growth for FY 25-26, backed by a healthy order book of 65-70% already secured. - Operating margins are expected to be sustained at around 20-23%, supported by improved yields, process efficiencies, and a favorable product mix. - EBITDA margin for Q3 was around 23%, with expectations to maintain similar margins going forward. - Profit after tax grew significantly, with Q3 PAT at INR 44 crores vs INR 29 crores last year; 9-month PAT increased 92% YoY to INR 121 crores. - Volume growth expected to be around 15% corresponding to the revenue growth of ~20%. - Continuous capacity expansions, debottlenecking, and new products (including JV with Givaudan) to support future earnings growth. - New product launches and entry into new geographies like Africa and India are expected to contribute positively. - The company aims to capitalize on all opportunities dynamically to sustain growth and margins.

- The company has a healthy order booking position with about 65% to 70% of orders already confirmed for calendar year 2025. - Around 70% of the business is contracted, primarily with large multinational F&F and FMCG companies, following calendar-year contracts. - The remaining 30% is mostly spot market sales and largely within the Indian market. - Management is confident about achieving revenue growth guided for FY25 and maintaining strong margins due to secured raw materials aligned with production volumes. - There is visibility and confidence for a good order book position for the next few quarters, supporting growth. - The company expects no major disruptions in the order book despite geopolitical uncertainties. - The current capacity expansion and debottlenecking exercises support volume growth for the next 1-2 years, aligning with the current order book.